Why VAL-083 for GBM
Based on historical data and our own research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of GBM.
O6-DNA methylguanine methyl-transferase (MGMT) is a DNA repair enzyme that causes resistance to temozolomide, the current standard of care in the treatment of GBM. High expression of the MGMT enzyme is strongly correlated with poor patient outcomes.3
We have demonstrated that VAL-083's cytotoxic mechanism has more potent activity against brain tumor cells in comparison to TMZ and can overcome resistance associated with MGMT, suggesting that VAL-083 has the potential to surpass TMZ as the current standard-of-care in the treatment of GBM.4
Our research is backed by historical clinical trials with VAL-083 that were conducted by the U.S. National Cancer Institute ("NCI") demonstrating activity against GBM that is comparable, or superior, to TMZ and other chemotherapies approved for the treatment of GBM.
We are conducting clinical trials with VAL-083 as a potential treatment for GBM patients that have failed or whose tumors express biological features, such as a high expression of MGMT, that make them unlikely to respond to currently available therapies.